Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival

2.

Rosenwald

A

,

Bens

S

,

Advani

R

, et al.

Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium

.

J Clin Oncol

.

2019

;

37

(

35

):

3359

-

3368

.

3.

Li

S

,

Wang

Z

,

Lin

L

, et al.

BCL6 rearrangement indicates poor prognosis in diffuse large B-cell lymphoma patients: a meta-analysis of cohort studies

.

J Cancer

.

2019

;

10

(

2

):

530

-

538

.

4.

El-Sharkawi

D

,

Sud

A

,

Prodger

C

, et al.

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications

.

Blood Cancer J

.

2023

;

13

(

1

):

54

.

5.

Khurana

A

,

Mwangi

R

,

Cerhan

JR

, et al.

Comparing clinical characteristics and outcomes of MYC and BCL6 double hit lymphoma (DHL- BCL6) with other aggressive B-cell lymphomas: understanding the impact of new WHO and International Consensus Classifications [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

67

.

6.

Alaggio

R

,

Amador

C

,

Anagnostopoulos

I

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1720

-

1748

.

7.

Campo

E

,

Jaffe

ES

,

Cook

JR

, et al.

The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee

.

Blood

.

2022

;

140

(

11

):

1229

-

1253

.

8.

Sandlund

JT

,

Kastan

MB

,

Kennedy

W

, et al.

A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia

.

Cancer Genet Cytogenet

.

2006

;

168

(

1

):

69

-

72

.

9.

Chong

LC

,

Ben-Neriah

S

,

Slack

GW

, et al.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology

.

Blood Adv

.

2018

;

2

(

20

):

2755

-

2765

.

10.

Zhang

C

,

Stelloo

E

,

Barrans

S

, et al.

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential

.

Leukemia

.

2024

;

38

(

3

):

621

-

629

.

11.

Ryan

RJH

,

Drier

Y

,

Whitton

H

, et al.

Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma

.

Cancer Discov

.

2015

;

5

(

10

):

1058

-

1071

.

12.

Ohno

H

,

Nakagawa

M

,

Kishimori

C

,

Fukutsuka

K

,

Honjo

G

.

Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas

.

Blood Cancer J

.

2017

;

7

(

6

):

e578

.

13.

Wright

GW

,

Huang

DW

,

Phelan

JD

, et al.

A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications

.

Cancer Cell

.

2020

;

37

(

4

):

551

-

568.e14

.

14.

Bartlett

NL

,

Wilson

WH

,

Jung

S-H

, et al.

Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303

.

J Clin Oncol

.

2019

;

37

(

21

):

1790

-

1799

.

15.

Chaganti

S

,

Illidge

T

,

Barrington

S

, et al.

Guidelines for the management of diffuse large B-cell lymphoma

.

Br J Haematol

.

2016

;

174

(

1

):

43

-

56

.

16.

McMillan

AK

,

Phillips

EH

,

Kirkwood

AA

, et al.

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial

.

Ann Oncol

.

2020

;

31

(

9

):

1251

-

1259

.

17.

Lamb

M

,

Painter

D

,

Howell

D

, et al.

Lymphoid blood cancers, incidence and survival 2005-2023: a report from the UK’s Haematological Malignancy Research Network

.

Cancer Epidemiol

.

2024

;

88

:

102513

.